90.95 USD
▲+0.15+0.17%
盘后 103.50 0.00%
2026-09-15
市值
$8.02B
市盈率
—
EPS
-2.01
股息率
—
52 周区间
14.51 – 110.18
成交量
858.48K
Beta
3.00
目标价
120.08
52W 低 14.5152W 高 110.18
价格走势
公司简介
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the α4β7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn’s disease); and SPY002 and SPY072 – anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also develo...